Sarcopenia: Ammonia metabolism and hepatic encephalopathy
- Author:
Ankur JINDAL
1
;
Rakesh Kumar JAGDISH
Author Information
- Publication Type:Review
- Keywords: Sarcopenia; Hepatic encephalopathy; Liver cirrhosis; Ammonia; Testosterone
- MeSH: Ammonia; Aspartic Acid; Fibrosis; Hepatic Encephalopathy; Hyperammonemia; Liver; Liver Cirrhosis; Metabolism; Motor Activity; Myostatin; Peptide Initiation Factors; Phosphorylation; Proteolysis; Quality of Life; Reactive Oxygen Species; Sarcopenia; Testosterone
- From:Clinical and Molecular Hepatology 2019;25(3):270-279
- CountryRepublic of Korea
- Language:English
- Abstract: Sarcopenia (loss of muscle mass and/or strength) frequently complicates liver cirrhosis and adversely affects the quality of life; cirrhosis related liver decompensation and significantly decreases wait-list and post-liver transplantation survival. The main therapeutic strategies to improve or reverse sarcopenia include dietary interventions (supplemental calorie and protein intake), increased physical activity (supervised resistance and endurance exercises), hormonal therapy (testosterone), and ammonia lowering agents (L-ornithine L-aspartate, branch chain amino acids) as well as mechanistic approaches that target underlying molecular and metabolic abnormalities. Besides other factors, hyperammonemia has recently gained attention and increase sarcopenia by various mechanisms including increased expression of myostatin, increased phosphorylation of eukaryotic initiation factor 2a, cataplerosis of α ketoglutarate, mitochondrial dysfunction, increased reactive oxygen species that decrease protein synthesis and increased autophagy-mediated proteolysis. Sarcopenia contributes to frailty and increases the risk of minimal and overt hepatic encephalopathy.
